Exits

Name Descriptionsort icon Event Date Acquired By
<a href="http://www.concertpharma.com" target="_blank">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. IPO 2014
<a href="http://tphase.com/home" target="_blank">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections. IPO 2013
<a href="http://www.hologic.com" target="_blank">CYTYC</a> Design, development, manufacturing, and marketing of medical devices focused on women's health IPO 1996
<a href="http://www.appliedbiosystems.com" target="_blank">PerSeptive BioSystems</a> Developer of high-technology purification, analysis and synthesis products Acquired 1998 <a href="http://www.appliedbiosystems.com" target="_blank">Applied Biosystems</a>
<a href="http://www.gilead.com/" target="_blank">CGI Pharmaceuticals, Inc.</a> Developing small molecule therapeutics for multiple oncology and immunology-based indications Acquired 2010 <a href="http://www.gilead.com/" target="_blank">Gilead</a>
<a href="http://www.bindtherapeutics.com/" target="_blank">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. IPO 2013
<a href="http://www.bg-medicine.com/" target="_blank">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. IPO 2011
<a href="http://www.bdbiosciences.com/instruments/accuri/" target="_blank">Accuri Cytometers, Inc.</a> Developing and manufacturing revolutionary, low-cost, high-performance flow cytometers for researchers. Acquired 2011 <a href="http://www.bdbiosciences.com/instruments/accuri/" target="_blank">Becton, Dickinson and Company</a>
<a href="http://www.t2biosystems.com/" target="_blank">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. IPO 2014
<a href="http://www.adnexustx.com" target="_blank">Adnexus Therapeutics</a> Developing new class of therapeutic compounds. Acquired 2007 <a href="http://www.bms.com" target="_blank">Bristol-Myers Squibb</a>
<a href="http://www.millipore.com" target="_blank">Epitome Biosystems</a> Developing novel protein measurement systems based on Protien Epitope Tag technology Acquired 2009 <a href="http://www.millipore.com" target="_blank">Millipore</a>
<a href="http://www.shire.com/shireplc/en/home" target="_blank">Pervasis Therapeutics, Inc.</a> Developing novel therapeutics to promote vascular repair. Acquired 2012 <a href="http://www.shire.com/shireplc/en/home" target="_blank">Shire</a>
<a href="http://www.auventx.com/" target="_blank">Resolvyx Pharmaceuticals, Inc.</a> Developing resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Acquired 2011 <a href="http://www.celtictherapeutics.com/" target="_blank">Celtic Therapeutics</a>
<a href="http://www.receptos.com/" target="_blank">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. IPO 2013
<a href="http://www.curis.com" target="_blank">Ontogeny, Inc.</a> Developmental biology insights for regenerative medicine therapies Acquired 2000 <a href="http://www.curis.com" target="_blank">Curis, Inc.</a>
<a href="http://www.agios.com/" target="_blank">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. IPO 2013
<a href="http://www.elevenbio.com/" target="_blank">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. IPO 2014
<a href="http://www.aveopharma.com" target="_blank">AVEO Pharmaceuticals, Inc.</a> Discovering, developing and commercializing cancer therapeutics. IPO 2010
<a href="http://www.acceleronpharma.com/" target="_blank">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. IPO 2013
<a href="http://www.combinatorx.com" target="_blank">Zalicus</a> Discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. IPO 2005